Market Size -
The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $9.96 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increased prevalence of cancer and diabetes, increased numbers of geriatric individuals, growing healthcare awareness, rise in research and development activities, increased numbers of clinical trials, Increased regulatory approval.
The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising prevalence of targeted diseases, an increasing geriatric population, rising prevalence of neurodegenerative diseases, growing number of cancer cases, increasing demand for skin transplantation, increasing awareness about regenerative medicine, collaborations and partnerships among key players, improving reimbursement for approved therapies. Major trends in the forecast period include the integration of artificial intelligence and machine learning, development of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, adoption of novel biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, integration of gene editing technologies.
Order your report now for swift delivery @
Scope Of Autologous Stem Cell And Non-Stem Cell Based Therapies Market
The Business Research Company's reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Autologous Stem Cell And Non-Stem Cell Based Therapies Market Overview
Market Drivers -
The autologous stem cell and non-stem cell based therapies market size has grown rapidly in recent years. It will grow from $8.58 billion in 2023 to $9.96 billion in 2024 at a compound annual growth rate (CAGR) of 16.1%. The growth in the historic period can be attributed to increased prevalence of cancer and diabetes, increased numbers of geriatric individuals, growing healthcare awareness, rise in research and development activities, increased numbers of clinical trials, Increased regulatory approval.
The autologous stem cell and non-stem cell based therapies market size is expected to see rapid growth in the next few years. It will grow to $18.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to rising prevalence of targeted diseases, an increasing geriatric population, rising prevalence of neurodegenerative diseases, growing number of cancer cases, increasing demand for skin transplantation, increasing awareness about regenerative medicine, collaborations and partnerships among key players, improving reimbursement for approved therapies. Major trends in the forecast period include the integration of artificial intelligence and machine learning, development of off-the-shelf allogeneic stem cell products, expansion of reimbursement policies, adoption of novel biomaterials, advancements in cell manufacturing technologies, adoption of autologous stem cell therapies, integration of gene editing technologies.
Market Trends -
Major companies in the autologous stem cell and non-stem cell-based therapies market are developing tumor-derived autologous T cell immunotherapy to enhance personalized cancer treatment approaches. Tumor-derived autologous T cell immunotherapy works by extracting T cells from a patient's tumor, expanding and activating them in the lab, and reinfusing them into the patient to enhance the immune system's ability to target and destroy cancer cells specifically. For instance, in February 2024, Iovance Biotherapeutics, a US-based biotechnology company, received accelerated approval from the Food and Drug Administration, a US-based federal agency, for Amtagvi (lifileucel), the first cellular therapy indicated for the treatment of adult patients with melanoma. Lifileucel is a tumor-derived autologous T-cell immunotherapy. It comprises a patient's naturally occurring immune cells called tumor-infiltrating lymphocytes (TILs). This allows the patient's immune system to recognize and attack the cancer more effectively.
The autologous stem cell and non-stem cell based therapies market covered in this report is segmented -
1) By Type: Autologous Stem Cells, Autologous Non-Stem Cells, Other Types
2) By Application: Cancer, Neurodegenerative Disorders, Cardiovascular Disease, Orthopedic Diseases, Other Applications
3) By End-User: Hospitals, Ambulatory Surgical Centers, Research Facilities, Other End Users
Get an inside scoop of the autologous stem cell and non-stem cell based therapies market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15729&type=smp
Regional Insights -
North America was the largest region in the autologous stem cell and non-stem cell based therapiesmarket in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autologous stem cell and non-stem cell based therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies -
Major companies operating in the autologous stem cell and non-stem cell based therapies market are Bayer AG, Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck & Co. Inc., Stemcell Technologies Inc., Dendreon Corporation, Vericel Corporation, Sangamo Therapeutics Inc., NEOSTEM, Orgenesis Inc., Adaptimmune Therapeutics, Stempeutics Research Pvt Ltd., MEDIPOST, Castle Creek Biosciences Inc., BrainStorm Cell Limited, Athersys Inc., Cytori Therapeutics Inc., Opexa Therapeutics, Gamida Cell, Regen BioPharma Inc., RepliCel Life Sciences, InGeneron Inc., BioCardia Inc., ReNeuron Group
Table of Contents
1. Executive Summary
2. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Characteristics
3. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Trends And Strategies
4. Autologous Stem Cell And Non-Stem Cell Based Therapies Market - Macro Economic Scenario
5. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Size and Growth
.
.
.
31. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Other Major And Innovative Companies
32. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Benchmarking
33. Global Autologous Stem Cell And Non-Stem Cell Based Therapies Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Autologous Stem Cell And Non-Stem Cell Based Therapies Market
35. Autologous Stem Cell And Non-Stem Cell Based Therapies Market Future Outlook and Potential Analysis
36.Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
